Global Stomach Cancer Treatment Market Assessment, By Treatment Type [Immunotherapy, Targeted Therapy, Chemotherapy, Others], By Type [Adenocarcinomas, Gastrointestinal Stromal Tumors (GISTs), Gastroesophageal Junction Cancer], By Drug Class [PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Other Drug Classes], By Route of Administration [Oral, Injectable], By Distribution Channel [Hospital Pharmacies, Specialty and Retail Pharmacies, Others], By Region, Opportunities and Forecast, 2018-2032F

Global stomach cancer treatment market is projected to witness a CAGR of 13.20% during the forecast period 2025-2032, growing from USD 5.41 billion in 2024 to USD 14.59 billion in 2032. The stomach cancer treatment market has gained significant traction in recent years. It is anticipated to keep growing at a notable pace owing to rising awareness, growing prevalence, and development of novel therapies.

Stomach cancer, or gastric cancer, primarily comes from the stomach lining and has multiple risk factors, among which are chronic gastritis, Helicobacter pylori infection, smoking, and dietary components like high salt intake. Genetic predispositions, including certain hereditary conditions, also contribute to its establishment. The treatment for stomach cancer often varies according to the individual stage and location. Treatment mostly focuses on surgery, which involves the removal of the tumor and surrounding tissue by partial or total gastrectomy. Chemotherapy is another common method that can be applied before surgery-neoadjuvant-to shrink the tumors or after surgery-adjuvant-to eliminate any residual cancer cells. In some instances, radiation therapy is used along with chemotherapy to ensure that the cancer cells are eradicated effectively. Advances include targeted therapies, which make use of drugs selective for particular characteristics of cancer cells or which enhance the immune response against the tumor. Furthermore, ongoing clinical research enhances the potential of the market.

For instance, in October 2023, according to an article published in the Annals of Surgical Oncology, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel and cisplatin are well tolerated and are associated with favorable oncologic and perioperative outcomes. This new approach to chemotherapy more than doubles the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the abdominal cavity.

Rising Prevalence of Stomach Cancers Brings Growth in Stomach Cancer Treatment Market

The prevalence of stomach cancer has been on the rise in recent years owing to different causal factors like genetic components, dietary changes, drastic lifestyle changes, and enhanced exposure to carcinogens. Specific reasons for stomach cancer infection in the stomach, long-standing acid reflux, and eating a lot of salty foods. As these causal factors are growing day by day with changing societal scenarios, the incidence of stomach cancer is also anticipated to keep rising. The incidence rate of stomach cancer is expected to decline slightly or remain stagnant in developed regions like North America and Europe, while it is anticipated to increase in developing regions like Africa and Asia. As per the American Cancer Society’s estimates for stomach cancer in the United States in 2024, about 16,160 cases in men and 10,730 cases in women are anticipated to be diagnosed. Additionally, around 10,880 deaths are expected from this type of cancer, with 6,490 men and 4,390 women affected. Stomach cancer represents about 1.5% of all new cancer diagnoses in the United States each year.

Growing Drug Development Supports Market Expansion

Growth in drug development is significantly boosting stomach cancer treatment market growth by developing innovative therapies that enhance patient outcomes and offering alternative treatment options. Targeted therapies and immunotherapies represent the most significant recent breakthroughs that have established several new drugs, including trastuzumab and zolbetuximab, targeted at specific molecular characteristics of cancer, such as HER2 and CLDN18.2. These therapies do not only provide alternatives for patients who do not respond to traditional chemotherapy but also demonstrate improved efficacy and reduced side effects, so they are increasingly adopted in clinical practice. Furthermore, ongoing clinical trials would be significant for the findings of new combinations of existing treatments, optimization of dosing regimens, and discovery of novel agents that may further improve survival rates.

For instance, in June 2023, AstraZeneca plc's MATTERHORN Phase III trial demonstrated that combining Imfinzi (durvalumab) with standard FLOT chemotherapy significantly improves pathologic complete response (pCR) in patients with resectable gastric and gastroesophageal junction cancers. The interim analysis showed a statistically meaningful increase in pCR compared to chemotherapy alone. The trial will continue to evaluate event-free survival and overall survival while safety profiles remain consistent with previous findings, indicating a potential new treatment approach for these cancers.

Adenocarcinoma Segment to Dominate the Stomach Cancer Treatment Market

The segment of gastric adenocarcinoma is expected to lead the market in stomach cancer treatment due to several compelling reasons. One such reason is the fact that gastric adenocarcinoma is the most common type of stomach cancer, and its growing prevalence catalyzes this market trend. As indicated by the International Agency for Research on Cancer, the annual burden of gastric cancer is expected to increase to about 1.8 million new cases and 1.3 million deaths by 2040, which should fuel the demand for effective treatments. In addition, advancements in targeted therapies and immunotherapy, especially the use of PD-1 inhibitors, are increasing the efficacy and consumption of their treatments. These have also made clinical trials increasingly successful, encouraging investments and studies in this field. Lastly, biosimilars, like trastuzumab, are expected to increase the number of treatment options and availability further. Consequently, the gastric adenocarcinoma segment is expected to capture a substantial market share, reflecting the continuous evolution of treatment strategies in line with rising incidence rates and technological advances in oncology.

North America Dominates Stomach Cancer Treatment Market

North America leads the stomach cancer treatment market due to several key factors. The region has a significant number of gastric cancer cases; the American Cancer Society estimates stomach cancer cases in the United States for 2024 to be about 26,890 new cases of stomach cancer (16,160 in men and 10,730 in women) and about 10,880 deaths from stomach cancer (6,490 men and 4,390 women). This rising incidence drives demand for effective treatment options. North America benefits from cutting-edge technology and research facilities, which facilitate the development and approval of innovative therapies. For instance, recent FDA approvals for new cancer drugs underscore the region's robust pharmaceutical landscape. This growth is further supported by increasing clinical trials and product launches to enhance treatment efficacy. With the growing economic position of North America on all fronts, particularly the healthcare sector, the market is anticipated to keep growing in the upcoming years.

Download Free Sample Report

Future Market Scenario (2025-2032F)

The most recent advancements in immunotherapy are significantly shaping the face of the stomach cancer treatment market. Among the most promising is immune checkpoint inhibitor (ICI) therapy, which has been impressively effective in clinical trials, such as nivolumab and pembrolizumab. These interact with the patient's immune cells to enhance their fight against cancer cells by improving survival in cases of advanced gastric cancer. Apart from ICIs, others emerging as effective strategies are adoptive cell therapies and cancer vaccines. For example, tumor-infiltrating lymphocyte (TIL) therapy has shown a remarkable increase in survival rates when combined with conventional treatments. More research is also being conducted on the antibody-drug conjugates (ADCs) that target particular biomarkers such as claudin18.2 for even more personalized treatment.

Report Scope

“Stomach Cancer Treatment Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global stomach cancer treatment market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2024
Historical Period	2018-2023
Forecast Period	2025-2032
Projected Growth Rate	CAGR of 13.20% between 2025 and 2032
Revenue Forecast in 2032	USD 14.59 billion
Segments Covered	Treatment Type, Type, Drug Class, Route of Administration, Distribution Channel
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profile	Novartis AG, Pfizer, Inc., Mylan N.V. (Viatris Inc.), F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd, Samsung Bioepis Co., Ltd., Bristol Myers Squibb Company
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global stomach cancer treatment market has been segmented into the following categories: 

• By Treatment Type
  • Immunotherapy
  • Targeted Therapy
    • Biologics
      • Keytruda
      • Herceptin
      • Enhertu
      • Cyramza
      • Vitrakvi
      • Rozlytrek
      • Vyloy
      • Others
    • Biosimilar
      • Ogivri
      • Herzuma
      • Ontruzant
      • Trazimera
      • Kanjinti
      • Others
    • Chemotherapy
      • Capecitabine
      • Cisplatin
      • Fluorouracil (5-FU)
      • Oxaliplatin
      • Others
    • Others
  • By Type
    • Adenocarcinomas
    • Gastrointestinal Stromal Tumors (GISTs)
    • Gastroesophageal Junction Cancer
  • By Drug Class
    • PD-1/PD-L1 Inhibitors
    • HER2 Antagonists
    • VEGFR2 Antagonists
    • Other Drug Classes
  • By Route of Administration
    • Oral
    • Injectable
  • By Distribution Channel
    • Hospital Pharmacies
    • Specialty and Retail Pharmacies
    • Others
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • South America
    • Middle East and Africa

Key Players Landscape and Outlook

Companies in the market are engaged in strategic initiatives such as partnerships and product launches to enhance their market presence and address the rising demand for effective treatments. Recent advancements in the market include regulatory approvals and acquisitions.

In October 2024, Astellas Pharma Inc.'s gastric cancer therapy, zolbetuximab (marketed as Vyloy), received approval from the U.S. FDA. The therapy earlier received approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) in August 2024. This first-in-class monoclonal antibody targets claudin 18.2-positive tumors in adults with locally advanced or metastatic gastric and gastroesophageal junction cancers. The therapy is to be used in combination with standard chemotherapy, offering a new treatment option that may extend patient survival and improve outcomes in this challenging cancer type.

In February 2024, AbbVie Inc. completed its acquisition of ImmunoGen Inc., which added ImmunoGen's flagship antibody-drug conjugate, ELAHERE, which targets folate receptor-alpha positive platinum-resistant ovarian cancer, to AbbVie's oncology portfolio. The deal aimed to enhance AbbVie's cancer treatment capabilities and expand its pipeline across various solid tumors and hematologic malignancies.

Key Players Operating in Global Stomach Cancer Treatment Market are:

• Novartis AG
• Pfizer, Inc.
• Mylan N.V. (Viatris Inc.)
• Hoffmann La Roche Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Celltrion Healthcare Co., Ltd
• Samsung Bioepis Co., Ltd.
• Bristol Myers Squibb Company

Markets and Data report answers the following questions:

• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and the market size and growth of each segment?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global stomach cancer treatment market, you may approach our team at info@marketsandata.com.